Navigation Links
China's monopoly on 17 key elements sets stage for supply crisis
Date:9/1/2010

China's monopoly on the global supply of elements critical for production of computer hard disc drives, hybrid-electric cars, military weapons, and other key products and its increasingly strict limits on exports is setting the stage for a crisis in the United States. That's the topic of the cover story of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

C&EN Senior Editor Mitch Jacoby and Contributing Editor Jessie Jiang explain that the situation involves a family of chemical elements that may soon start to live up to their name, the "rare earths." China has virtually cornered the global market on them, and produces most of the world's supply. Since 2005, China has been raising prices and restricting exports, most recently in 2010, fostering a potential supply crisis in the U.S.

The article describes how the U.S. is now responding to this emerging crisis. To boost supplies, for instance, plans are being developed to resume production at the largest U.S. rare-earth mine Mountain Pass in southern California which has been dormant since 2002. The U.S. Department of Energy and the Department of Defense are among the government agencies grappling with the problem.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Study finds that caring for an elderly, sick spouse sometimes has positive elements
2. Elements Therapeutic Massage Announces Franchise Expansion Plan for Massachusetts
3. Research defines timeframes, factors to deem early stage lung cancer cured
4. Millions of Americans in early stages of kidney disease need stroke monitoring
5. Taking to the Stage to Battle Mental Illness
6. UCLA scientists isolate the first stages of tissue production in human embryonic stem cells
7. Key pathway in end-stage prostate cancer tumor progression blocked
8. Study examines reasons patients with early stage lung cancer do not have surgery
9. Late-stage ovarian cancer shows promise in 2-drug phase I trial
10. Late-stage ovarian cancer shows promise in two-drug phase I trial
11. Thyroid ultrasound takes center stage at Caesars Palace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor ... proactively address potential cybersecurity threats before they happen. The annual list of ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
(Date:5/23/2017)... ... 23, 2017 , ... The Gallery of Cosmetic Surgery, founded ... to announce a new treatment option called Vivace Microneedling. This treatment option is ... body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, best-in-class ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... video chat as a standard feature on its secure clinical communication platform. The ... voice to video depending on the type and urgency of a situation. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... treatment using the SPEED System™ Orthodontics, with or without a referral, from the ... in El Segundo, CA, who is skilled in providing patients with the custom, ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... MAITLAND, Fla. , May 22, 2017 /PRNewswire/ ... industry as a whole continue to make the ... evidence becomes increasingly important for ensuring positive patient ... Key industry stakeholders are shifting focus away from ... results and effects of long-term specialty drug therapy ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
Breaking Medicine Technology: